Genovis AB initiates sales of GlyCLICK™

Today Genovis is launching GlyCLICK , a product for specific labeling of antibodies for purposes such as development of biopharmaceuticals. 

GlyCLICK™ is the first of a series of products based on a technology platform in which Genovis’ unique enzyme GlycINATOR  is combined with SiteClick™ technology from Life Technologies. GlyCLICK is a new technology in an expanding market for applications in antibody development, preclinical imaging and antibody drug conjugates (ADCs). The market for biopharmaceuticals is large and many pharmaceutical companies are looking for new and improved technologies that link chemotherapy to antibodies.

“We have now expanded our portfolio with a completely new type of product that will enable us to develop an additional business area. The strength of the GlyCLICK™ platform is its predictability: the antibody is always labeled at exactly the same site and with the same number of markers, resulting in a precise and accurate end product. The technology is also compatible with previously developed antibodies,” says Fredrik Olsson, Chief Executive Officer.

More about GlyCLICK™  

GlyCLICK is a platform for labeling antibodies at the same site (site specific) each time, with high reproducibility and with a broad range of applications. GlyCLICK can be used to label antibodies with markers for microscopy, preclinical imaging or to activate the antibody for labeling in chemotherapy. Labeling antibodies with various markers is a technique used in several areas of pharmaceutical research and development. With the technology currently available in the market, the marker can attach randomly in different places on the antibody, and in many cases it could have a negative effect on the function of the antibody. In addition, the position of the marker may vary depending on the antibody that is labeled. Using the new GlyCLICK technology platform, the label always attaches at precisely the same site and it is possible to label with many different markers, which makes the technology both versatile and scalable.

For more information about GlyCLICK™ http://www.genovis.com/products/glyclick/  

SiteClick™  

Genovis has a license for SiteClick™ from Life Technologies Corporation. The SiteClick™ brand belongs to Life Technologies Corporation.  

For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046 (0)46 -101233  fredrik.olsson@genovis.com


ABOUT GENOVIS

Genovis’ business concept is to apply its knowledge and imagination to design and provide innovative tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes all over the world in innovative product formats that facilitate development and quality control of biological drugs. 

The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (USA). Genovis shares are listed on Nasdaq First North Stockholm and Penser Bank is the Company’s Certified Advisor, T: +46 (0)8-463 83 

This press release is a translation of the Swedish original. In the event of any discrepancy between this translation and the Swedish original, the Swedish version shall prevail.

This information is information that Genovis AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out above, on April 4, 2017.




About Us

Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging. Genovis shares are listed on NASDAQ OMX First North

Subscribe

Documents & Links